Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Berlin, C; Kowalewski, D J; Schuster, H; Mirza, N; Walz, S; Handel, M; Schmid-Horch, B; Salih, H R; Kanz, L; Rammensee, H-G; Stevanovic, S; Stickel, J S

Berlin, C; Kowalewski, D J; Schuster, H; Mirza, N; Walz, S; Handel, M; Schmid-Horch, B; Salih, H R; Kanz, L; Rammensee, H-G; Stevanovic, S; Stickel, J S.

Affiliation

Berlin C; 1] Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany [2] Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.
Kowalewski DJ; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Schuster H; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Mirza N; 1] Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany [2] Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.
Walz S; 1] Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany [2] Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.
Handel M; Hospital Group South-West, Department of Orthopedics, Calw, Germany.
Schmid-Horch B; Institute for Clinical and Experimental Transfusion Medicine, University of Tübingen, Tübingen, Germany.
Salih HR; 1] Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany [2] Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kanz L; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.
Rammensee HG; 1] Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany [2] Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stevanovic S; 1] Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany [2] Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stickel JS; 1] Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany [2] Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.

Leukemia ; 29(3): 647-59, 2015 Mar.

Article de En | MEDLINE | ID: mdl-25092142

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Peptides / Antigènes d'histocompatibilité de classe I / Leucémie aigüe myéloïde / Antigènes d'histocompatibilité de classe II / Immunothérapie active / Vaccins anticancéreux / Protéines tumorales Type d'étude: Observational_studies / Risk_factors_studies Langue: En Journal: Leukemia Sujet du journal: HEMATOLOGIA / NEOPLASIAS Année: 2015 Type de document: Article Pays d'affiliation: Allemagne

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google